598 related articles for article (PubMed ID: 32517959)
1. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252
[TBL] [Abstract][Full Text] [Related]
3. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
Beer PA; Cooke SL; Chang DK; Biankin AV
Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
[No Abstract] [Full Text] [Related]
4. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
5. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
6. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
7. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
[TBL] [Abstract][Full Text] [Related]
9. Molecular Tumor Boards: Realizing Precision Oncology Therapy.
Patel M; Kato SM; Kurzrock R
Clin Pharmacol Ther; 2018 Feb; 103(2):206-209. PubMed ID: 29134641
[TBL] [Abstract][Full Text] [Related]
10. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
11. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
13. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
Kotelnikova EA; Pyatnitskiy M; Paleeva A; Kremenetskaya O; Vinogradov D
Oncotarget; 2016 Aug; 7(32):52493-52516. PubMed ID: 27191992
[TBL] [Abstract][Full Text] [Related]
14. [Precision oncology and molecular tumor boards].
Mack E; Horak P; Fröhling S; Neubauer A
Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
[TBL] [Abstract][Full Text] [Related]
15. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
16. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
19. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
20. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
